FCM
RPRX icon

Fieldview Capital Management’s Royalty Pharma RPRX Stock Holding History

Fieldview Capital Management’s Portfolio RPRX Stock Details RPRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$658K Sell
11,741
-29,569
-72% -$1.54M 0.19% 165
2026
Q1 		$1.98M Sell
41,310
-55,442
-57% -$2.43M 0.58% 26
2025
Q4 		$3.74M Buy
+96,752
New +$3.69M 0.64% 36

Other funds holding RPRX

Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Swedbank
Swedbank Stockholm, Sweden $116B AUM 46.87% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Fieldview Capital Management's RPRX Position: Q2 2026 in Review

Fieldview Capital Management reduced its Royalty Pharma (RPRX) stake by 72% in Q2 2026, selling an estimated $1.54M and leaving 11,741 shares worth $658K. The position accounts for 0.19% of the portfolio, ranked #165.

Fieldview Capital Management first reported a position in RPRX in Q4 2025 and has held it in 3 quarters since. The position peaked at $3.74M in Q4 2025. 645 funds tracked by Wall St. Rank hold RPRX as of Q2 2026.

  • Fieldview Capital Management held 11,741 shares of Royalty Pharma worth $658K as of Q2 2026.
  • Fieldview Capital Management sold 29,569 Royalty Pharma shares in Q2 2026, an estimated $1.54M.
  • Royalty Pharma made up 0.19% of Fieldview Capital Management's portfolio in Q2 2026, its #165 holding.
  • Fieldview Capital Management first reported a position in Royalty Pharma in Q4 2025 and has held it in 3 quarters since.
  • Fieldview Capital Management's Royalty Pharma position peaked at $3.74M in Q4 2025.
  • 645 funds tracked by Wall St. Rank held Royalty Pharma as of Q2 2026.

Based on Fieldview Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.